Palisade Bio has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PALI-2108 in Crohn’s disease. The clearance allows the compound to progress into clinical testing for this indication, building on the company’s existing development programme in ulcerative colitis (UC) and marking an expansion of its Phase 2 work across inflammatory bowel disease (IBD).
Background Context
Inflammatory bowel disease encompasses Crohn’s disease (CD) and ulcerative colitis (UC), both chronic, relapsing conditions driven by dysregulated immune activity in the gastrointestinal tract. Although biologic and small-molecule therapies have expanded treatment options over the past two decades, a substantial proportion of patients do not achieve durable remission, lose response over time, or experience side effects that limit long-term use. This has sustained interest across the pharmaceutical sector in developing new compounds with alternative mechanisms of action, particularly agents that might offer more targeted or gut-restricted activity than existing systemic therapies.
Key Findings
According to Palisade Bio, the FDA’s clearance of the IND application permits PALI-2108 to move forward into clinical evaluation specifically for Crohn’s disease, in addition to the compound’s ongoing assessment in ulcerative colitis. The company describes this as an expansion of its Phase 2 development programme across the two principal forms of IBD. Palisade Bio frames the announcement within the broader context of unmet need in IBD, noting that many patients continue to seek treatment despite the range of therapies already available. The company has not, in the material reviewed, disclosed specific trial design details, patient numbers, or efficacy data at this stage, as the announcement centres on the regulatory clearance itself rather than clinical trial results.
Clinical Relevance
For clinicians and patients, an IND clearance represents a regulatory milestone rather than evidence of clinical benefit; it permits a company to begin or extend human trials of an investigational compound but does not indicate efficacy or safety outcomes. Nonetheless, the expansion of a Phase 2 programme to cover both Crohn’s disease and ulcerative colitis signals continued pharmaceutical investment in IBD, a field where clinicians report that a meaningful subset of patients still experience inadequate disease control on existing options. IBD teams and dietitians may wish to note early-stage developments such as this while recognising that clinical translation, if it occurs, remains some years away.
Reference
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD [press release]. BioSpace; 2025. Available from: https://www.biospace.com/press-releases/palisade-bio-receives-fda-clearance-of-ind-for-pali-2108-in-crohns-disease-expanding-phase-2-development-across-ibd
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.